ORBIMED ADVISORS LLC
Q3 2021 13F-HR Holdings
Net value change ($000)
-787,437
(-8.0%)
New positions
27
Sold out positions
15
Turnover %
11.5%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q2 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IVVD | 227,399 | NEW |
| ZBH | 96,715 | NEW |
| HCA | 47,039 | NEW |
| ERAS | 45,991 | NEW |
| Seagen Inc. | 45,506 | NEW |
| BIIB | 42,937 | 184.0% |
| CTKB | 41,174 | NEW |
| Mirati Therapeutics, Inc. | 38,727 | 19.0% |
| HELP | 29,463 | NEW |
| PRLD | 26,304 | 9.2% |
Top Reduces (Value $000, Stocks/ETFs)
| SPRY | -182,772 | -67.7% |
| SpringWorks Therapeutics, Inc. | -115,672 | -23.2% |
| AUPH | -78,655 | -100.0% |
| Acutus Medical, Inc. | -69,604 | -74.8% |
| EWTX | -65,958 | -22.2% |
| ASND | -58,916 | -100.0% |
| NTRA | -58,349 | -25.0% |
| VRTX | -55,665 | -25.9% |
| ABCL | -53,123 | -38.8% |
| ELV | -50,963 | -39.8% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
9,898
(0.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|